Efficacy and Safety Study of Panobinostat in Participants With Metastatic Hormone Refractory Prostate Cancer
Status:
Completed
Trial end date:
2010-11-05
Target enrollment:
Participant gender:
Summary
This Phase II single dose study was designed to characterize the safety, tolerability, and
efficacy of intravenous (i.v.) panobinostat as a single-agent treatment in participants with
hormone refractory prostate cancer.